Protocol Ledger

NCT05678959 · Phase III · TERMINATED

Long-term Extension Study of Ligelizumab in Food Allergy

Interventional Phase III clinical trial protocol NCT05678959 sponsored by Novartis in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-04-27 Enrollment: 163 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05678959
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)163 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05678959
Protocol FieldVerified Registry Value
NCT IdentifierNCT05678959
Consolidated Lead SponsorNovartis
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment163 participants (ACTUAL)
Registered Start Date2023-04-27
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05678959
Hospital Research SiteLocationSite Profile
Arkansas Children's HospitalLittle Rock, AROpen Hospital Dossier ->
Johns Hopkins Hospital and Kimmel Cancer CenterBaltimore, MDOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI